Koshland Compounding Pharmacy: 2026 Pricing & Peptide Access Guide

Introduction: Why “Koshland Compounding Pharmacy” Searches Are Shifting

Most people who search for Koshland Pharm already know the business. They want an address, business hours, or a phone number for the San Francisco compounding pharmacy. A growing share of these searches, however, come from patients frustrated by unclear pricing, limited shipping, or the unavailability of certain peptides.

This guide does not repeat the usual review of credentials or shipping maps. Instead, it functions as a decision tool focused on two friction points that most existing coverage underdevelops: pricing opacity and the peptide-compounding pause. It also addresses a third issue, insurance billing. Each section includes a practical comparison, and the guide ends with a self-assessment checklist that patients can complete in a few minutes.

The timing matters. In July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) held a landmark peptide vote. Nonresident pharmacy licensing has also matured into a nationwide licensing framework. Together, these changes make late 2026 a natural point for patients to reassess where they fill compounded prescriptions.

Koshland Pharm at a Glance: What’s Already Well Documented

Koshland Pharm has a solid track record:

• Founded: 2009, headquartered at 301 Folsom St., Suite B, San Francisco, CA
• Structure: Privately held, with 11 to 50 employees
• Accreditation: In 2010, it became the first San Francisco compounding pharmacy to earn PCAB accreditation. It still markets itself as the city’s only PCAB-accredited compounder.
• Leadership: CEO and Head Pharmacist Peter Koshland, PharmD, who has a 20-year pharmacy career
• Recognition: Named to the San Francisco Business Times’ 100 Fastest Growing Bay Area Companies in 2013 and 2014
• Specialties: Hormone replacement, veterinary medications, pain management, dental, thyroid, sinus, pediatric, dermatology, and urology compounds
• Reputation: A 4.4-star Yelp rating across 178 reviews. This is strong but not flawless, and pricing complaints come up repeatedly.

PCAB accreditation is notable; fewer than 1% of the roughly 3,000 U.S. compounding pharmacies hold it. This guide assumes readers already know these basics, so it skips the geographic shipping-tier breakdowns covered elsewhere.

Friction Point #1: Koshland’s Pricing Opacity

Koshland Pharm publishes no public pricing or formulary cost list. Patients must call or request a quote before they learn what they will pay out of pocket. Several Yelp reviewers describe Koshland’s prices as “significantly higher” than those of other compounding pharmacies.

This matters most for self-pay compounded drugs such as GLP-1s and peptides, because there is no insurance benchmark to anchor expectations. Market data offers some reference points: compounded semaglutide typically runs $150 to $500 per month nationally, while brand-name GLP-1 list prices run roughly $1,000 to $1,400 per month. When a pharmacy’s quotes land near the top of the compounded range or above it, patients deserve to know before they commit.

Side-by-Side Pricing Transparency Table

Factor	Koshland Pharm	Nationwide Compounding Rx®
Pricing visibility	Call-for-quote; no public list	Quotes provided on request; pricing not published online
Typical GLP-1/peptide monthly cost	Not published; reviewers report above-market pricing	Not published; request a quote for the specific prescription
Membership or hidden fees	Not publicly disclosed	Patients should request an itemized quote that confirms there are no added fees
Insurance billing	Caremark and Express Scripts PBM billing (since 2013)	Peptide and GLP-1 formulations are typically self-pay; confirm directly
Operating footprint	Single San Francisco location	Multi-state licensure from Scottsdale, AZ

Structural costs help explain the difference. San Francisco has some of the highest commercial rents and labor costs in the country, and a single-location pharmacy there must spread that overhead across a California-only patient base. A pharmacy licensed in multiple states can spread fixed costs over a larger volume, which may support more consistent pricing. The key differentiator is not who is cheaper on any given day; it is whether patients can see and compare the cost before they commit.

Why Pricing Transparency Matters for Compounded Medications

Compounded drugs are not FDA-approved commercial products, so there is no standardized list price or insurance benchmark. Patients carry more of the research burden. A few habits help:

• Request itemized quotes before committing to a pharmacy.
• Compare cost per mg or per month, not per vial, because vial sizes and concentrations vary.
• Confirm refill pricing as well as the first fill.

Because most peptide and GLP-1 compounding is cash-pay, transparent pricing carries extra weight for these patients.

Friction Point #2: The Koshland Peptide-Compounding Pause

Koshland Pharm has publicly confirmed that it is not currently compounding peptides like BPC-157 while it waits for FDA clarity.

The trigger was the FDA Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026. The committee voted to recommend adding six peptides to the 503A Bulks List:

• BPC-157
• KPV
• TB-500
• MOTS-c
• Epitalon
• Semax

It rejected a seventh, emideltide. Analyses from Holland & Knight, NCPA, and Mintz all emphasize the same point: the vote is non-binding until HHS acts. That is why cautious pharmacies like Koshland have paused rather than resumed compounding these substances.

The uncertainty will last well into 2027. A second PCAC meeting is scheduled before the end of February 2027 to evaluate five more peptides: cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor.

For patients who use or want BPC-157 and similar peptides through Koshland, there is currently no clear timeline for resumption.

Peptide/GLP-1 Availability Comparison Table

Pharmacy	Formulation Type	Current Status	Regulatory Basis
Koshland Pharm	BPC-157 and peptides under PCAC review	Paused	Awaiting HHS action on the non-binding PCAC vote
Koshland Pharm	Hormones, pain, dermatology, and other core compounds	Available (California only)	Standard 503A compounding
Nationwide Compounding Rx®	GLP-1/peptide support formulations	Offered; specific peptides should be confirmed per prescription	503A compounding, subject to state licensing tiers
Nationwide Compounding Rx®	BHRT, pain, dermatology, pediatrics, sports medicine	Available	Standard 503A compounding

Pharmacies make their own risk-based decisions about which bulk substances to compound, even before final FDA listing. As a result, availability can legitimately differ between two PCAB-accredited pharmacies. Peptide availability remains fluid across the industry, so patients should confirm current formulary status directly with any pharmacy before assuming a product is available.

What This Regulatory Uncertainty Means for Patients Right Now

• A favorable vote does not guarantee access. Patients should not expect Koshland, or any pharmacy, to resume BPC-157 compounding immediately.
• Ask specific questions. Patients should ask each prospective pharmacy which peptides it is compounding now and which are paused.
• Accreditation is not a formulary. PCAB accreditation governs quality and safety standards, including compliance with USP <795>, <797>, and <800>. It does not determine which substances a pharmacy chooses to compound. Many consumers confuse the two.

Friction Point #3: Insurance & PBM Billing Inconsistency

In 2013, Koshland began billing through the pharmacy benefit managers (PBMs) Caremark and Express Scripts. This covers plans such as Anthem Blue Cross, Health Net, and Aetna. The pharmacy chose these PBMs because they tend to cover customized prescriptions more often.

Even so, coverage for compounded drugs is inconsistent across the industry, regardless of which PBMs a pharmacy bills. Approval often depends on ingredient-level formulary rules, not just on whether the pharmacy is enrolled. Most GLP-1 and peptide compounds remain cash-pay no matter which PBM relationships a pharmacy has, because they are not FDA-approved commercial products.

Billing Factor	Koshland Pharm	Typical Nationwide Compounder Model
Named PBM relationships	Caremark, Express Scripts	Varies; often focused on self-pay
Hormone/BHRT coverage	Possible, depending on ingredients	Possible, depending on ingredients and plan
GLP-1/peptide coverage	Rarely covered	Rarely covered; flat self-pay is common
Realistic expectation	Verify each compound	Request a self-pay quote up front

The Patient Self-Assessment Checklist: Should I Stay Local or Go Nationwide?

This checklist pulls together the three friction points above. Each question has a yes or no answer, and patients can work through all of them in a few minutes.

Geography & Shipping Fit

• Is the patient located in California, with in-store pickup or in-state delivery available? If yes, Koshland remains viable on logistics alone.
• Is the patient located outside California? Koshland’s own website states that it “can only ship within the state of California.” Out-of-state patients therefore need a pharmacy licensed for nationwide shipping.

Since Massachusetts implemented its nonresident pharmacy licensing regime on May 1, 2025, every U.S. state has had a formal licensing pathway for out-of-state pharmacies. Properly licensed pharmacies can now ship legally nationwide.

Pricing Sensitivity

• Has the patient compared Koshland’s quote with at least one flat-rate alternative for the same formulation?
• Is published or clearly quoted pricing important to the patient’s decision?

Before committing to a long-term compounding relationship, patients should request written quotes from several PCAB-accredited pharmacies.

Formulation Needs (Peptides & GLP-1s)

• Does the treatment plan currently require BPC-157 or another paused peptide?
• Has the prescriber confirmed Koshland’s current formulary status for the specific medication?

If the needed formulation is paused at Koshland, patients should check current availability with a nationwide-licensed alternative such as Nationwide Compounding Rx®.

Insurance & Payment Preferences

• Does the patient’s plan use Caremark or Express Scripts, and has coverage been confirmed for the specific compound, not just the pharmacy?
• Is the patient prepared to pay cash for peptide or GLP-1 formulations, whichever pharmacy they choose?

Patients should call their PBM directly to verify coverage. PBM acceptance at a pharmacy does not guarantee reimbursement for a particular compound.

Scoring the Checklist: Interpreting Your Answers

Several “no” answers in the geography, pricing transparency, or formulation sections suggest it is time to evaluate a nationwide-licensed, PCAB-accredited alternative. Whatever the result, accreditation and compliance standards such as PCAB and USP 800 should remain non-negotiable.

Where Nationwide Compounding Rx® Fits for Patients Koshland Can’t Serve

Nationwide Compounding Rx® is a PCAB-accredited, USP 800-compliant compounding pharmacy based in Scottsdale, Arizona. It is a practical option for patients limited by Koshland’s pricing, its peptide pause, or its California-only shipping.

Capabilities include:

• GLP-1/peptide support formulations
• Bioidentical Hormone Replacement Therapy (BHRT), with formulas that can be adjusted at each refill based on lab results
• Pain management topicals designed to reduce systemic side effects
• Dermatology, pediatric, and sports medicine compounds

Operational strengths include:

• A 1-2 business day turnaround, with same-day pickup for some medications
• Independent third-party testing
• High-grade chemicals sourced from FDA-inspected and cleared vendors
• A team with more than 40 years of combined experience

Providers work with the pharmacy through a structured Connect → Collaborate → Create → Care partnership framework. Separate secure Provider and Patient Portals simplify prescription submission, order tracking, and refill requests.

Availability depends on medication type, the pharmacy’s three-tier state licensing structure, and individual prescription requirements. Patients should confirm current formulary status directly before transferring a prescription.

A Note on the Regulatory Environment Ahead

Patients evaluating any nationwide compounder should keep three developments in mind:

• The SAFE Drugs Act of 2025 (H.R. 6509). Introduced December 9, 2025, this bill would require pharmacies that ship more than 20 out-of-state prescriptions of a given drug to report that activity to the FDA.
• Section 503A’s 5% cap. Pharmacies in states without an FDA Memorandum of Understanding (MOU) may ship no more than 5% of their total prescription volume out of state. That framework remains unresolved after a 2021 court remand.
• Licensure is the real test. Proper state-by-state licensure, not marketing claims, is what makes a “nationwide” compounder legitimate. As legal analysts note, the shipment itself creates the licensing obligation in the destination state.

Conclusion: Making an Informed Choice in 2026

Three friction points shape the Koshland decision in 2026: pricing opacity, the peptide-compounding pause, and inconsistent PBM coverage.

Koshland Pharm remains a credible, PCAB-accredited option for California patients whose needs fit its current formulary and budget. Patients who live outside California, are priced out, or need paused peptide formulations have a legitimate, equally accredited nationwide alternative. The self-assessment checklist, not brand loyalty or geography alone, should guide the final decision.

Get a Pricing Quote from Nationwide Compounding Rx®

Patients who answered “no” to several checklist questions can contact Nationwide Compounding Rx® for a formulation and pricing consultation.

• Phone: (480) 499-8379
• Website: nationwidecompounding.com
• Hours: Monday-Friday, 7:00 AM-3:30 PM
• Address: 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260

The secure Patient Portal offers an easy way to start a prescription transfer or request support. Providers evaluating a compounding partner can use the Provider Portal or request a direct consultation through the Connect → Collaborate → Create → Care process.